google-site-verification: googlec7193c3de77668c9.html
Wednesday , October 28 2026

FDA approves Enhertu as neoadjuvant, adjuvant treatment for breast cancer

[
The U.S. Food and Drug Administration has approved AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.


Source link

Advertisements

See also  Rethinking newborn screening for critical congenital heart disease

Check Also

Earlier introduction of HPV vaccine improves initiation, completion by age 13

[ Credit: CC0 Public Domain Introducing the human papillomavirus (HPV) vaccine at ages 9 to …

Higher medical fees increase expected pain and reduce willingness to book appointments

[ Rising out-of-pocket medical costs do more than drain a patient’s bank account. New research …

Where humans build, mosquitoes follow—bringing dengue, West Nile and other diseases with them

[ Temperatures are becoming more conducive to disease-spreading mosquitoes. The map reflects the number of …

Leave a Reply

Available for Amazon Prime